GeoVax Expands Global Strategy with European Foothold in the United Kingdom

GeoVax Labs, a clinical-stage biotechnology company, is set to broaden its global research and development capabilities by establishing a strategic presence in Europe, with the United Kingdom serving as its initial operational hub. This expansion aims to leverage European scientific expertise and collaborative networks to advance the company's vaccine and immuno-oncology programs.

The company's European strategy includes multiple strategic connections that will support its development efforts. By bringing onboard Professor Teresa Lambe from the Oxford Vaccine Group to its Scientific Advisory Board, GeoVax gains access to critical expertise in vaccine design. Professor Lambe, who played a significant role in developing the Oxford/AstraZeneca COVID-19 vaccine, represents a key scientific asset for the company's future research initiatives.

Manufacturing and technological partnerships form another crucial aspect of GeoVax's European expansion. The company has existing relationships with Oxford Biomedica PLC in the UK and France, as well as a licensing agreement with ProBioGen AG in Germany for utilizing advanced cell line technologies for vaccine manufacturing. These partnerships provide a robust infrastructure for developing and scaling innovative vaccine solutions.

The expansion is particularly significant for GeoVax's two primary focus areas: infectious disease vaccines and immuno-oncology therapies. The company's lead immuno-oncology candidate, Gedeptin®, is currently in clinical development for treating advanced head and neck cancers, with potential applications in treating various solid tumors when combined with immune checkpoint inhibitors.

Dr. Deborah Spencer, an expert in industry-academic partnerships, has been engaged to facilitate and coordinate initiatives across the UK and Europe. Her involvement underscores the company's commitment to building strong collaborative networks that can accelerate research and development processes.

GeoVax's President and CEO, David Dodd, emphasized the strategic importance of this expansion, noting that the globally recognized expertise of European collaborators will significantly enhance the company's research capabilities. The move reflects a broader commitment to global innovation in vaccine and immuno-oncology development.

The company's ongoing clinical programs, including a BARDA-funded Phase 2b trial for its COVID-19 vaccine candidate GEO-CM04S1 and multiple Phase 2 clinical trials exploring vaccine efficacy for immunocompromised patients, stand to benefit from this enhanced European presence.

By establishing this strategic foothold, GeoVax is positioning itself to accelerate scientific innovation, leverage international expertise, and potentially bring more advanced therapeutic solutions to global healthcare markets.